Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hana Pharm Co., Ltd. (293480.KS)
Hana Pharm Co., Ltd. is a pharmaceutical enterprise that manufactures and supplies a diverse range of medicinal goods to both domestic South Korean and international markets. Its comprehensive product line covers various therapeutic categories, such as anesthetics, potent narcotic pain relievers, anti-nausea agents, muscle relaxants, and treatments targeting the cardiovascular, endocrine, gastrointestinal, respiratory, and central nervous systems. Furthermore, the company offers antibiotics, dermatological preparations, urological medications, osteoporosis therapies, and medications for pain, fever, and inflammation. The firm was established in 1958 and has its corporate headquarters located in Seoul, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.10% | +6.25% | +0.92% | -10.45% | -13.66% | -10.53% | -11.96% | -32.05% | -56.94% | -67.28% | -67.28% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+6.3% Q1'26: +8.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-59.6% Q1'26: +130.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+2.2% Q1'26: -41.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+10.8% Q1'26: +11.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+4.3% Q1'26: +5.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+2.7% Q1'26: +2.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.59× Q1'26: 1.59× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
152.83B
est: 153.80B (-0.6%)
|
166.35B
est: 167.40B (-0.6%)
|
177.31B
est: 177.00B (+0.2%)
|
196.41B
est: 197.40B (-0.5%)
|
210.84B
est: 214.80B (-1.8%)
|
224.46B
est: 232.70B (-3.5%)
|
225.34B
est: 228.90B (-1.6%)
|
239.50B
est: 243.40B (-1.6%)
|
257.30B
257.30B – 257.30B
+5.7% YoY
|
270.90B
270.90B – 270.90B
+5.3% YoY
|
290.70B
290.70B – 290.70B
+7.3% YoY
|
| EBITDA |
37.51B
est: 27.09B (+38.5%)
|
39.12B
est: 29.48B (+32.7%)
|
33.54B
est: 31.17B (+7.6%)
|
41.65B
est: 34.77B (+19.8%)
|
37.74B
est: 37.83B (-0.2%)
|
34.68B
est: 40.98B (-15.4%)
|
32.87B
est: 38.72B (-15.1%)
|
36.95B
est: 41.17B (-10.2%)
|
43.52B
43.52B – 43.52B
+5.7% YoY
|
45.82B
45.82B – 45.82B
+5.3% YoY
|
49.17B
49.17B – 49.17B
+7.3% YoY
|
| EBIT |
32.63B
est: 22.28B (+46.5%)
|
34.92B
est: 24.25B (+44.0%)
|
28.55B
est: 25.64B (+11.3%)
|
35.89B
est: 28.59B (+25.5%)
|
31.30B
est: 31.11B (+0.6%)
|
27.03B
est: 33.71B (-19.8%)
|
25.15B
est: 30.74B (-18.2%)
|
25.92B
est: 32.69B (-20.7%)
|
34.56B
34.56B – 34.56B
+5.7% YoY
|
36.38B
36.38B – 36.38B
+5.3% YoY
|
39.04B
39.04B – 39.04B
+7.3% YoY
|
| Net Income |
26.17B
est: 24.71B (+5.9%)
|
28.30B
est: 27.08B (+4.5%)
|
14.89B
est: 14.45B (+3.0%)
|
28.01B
est: 29.48B (-5.0%)
|
24.31B
est: 24.53B (-0.9%)
|
22.33B
est: 23.63B (-5.5%)
|
21.25B
est: 24.06B (-11.7%)
|
8.78B
est: 13.03B (-32.6%)
|
22.16B
22.16B – 22.16B
+70.1% YoY
|
23.73B
23.73B – 23.73B
+7.1% YoY
|
24.79B
24.79B – 24.79B
+4.5% YoY
|
| SGA |
24.11B
est: 33.38B (-27.8%)
|
25.67B
est: 36.33B (-29.4%)
|
26.65B
est: 38.42B (-30.6%)
|
41.02B
est: 42.84B (-4.3%)
|
48.16B
est: 46.62B (+3.3%)
|
55.25B
est: 50.51B (+9.4%)
|
56.67B
est: 53.86B (+5.2%)
|
57.87B
est: 57.27B (+1.0%)
|
60.54B
60.54B – 60.54B
+5.7% YoY
|
63.74B
63.74B – 63.74B
+5.3% YoY
|
68.40B
68.40B – 68.40B
+7.3% YoY
|
| EPS |
1,794.94
est: 1,428.18 (+25.7%)
|
1,616.79
est: 1,565.45 (+3.3%)
|
860.74
est: 835.45 (+3.0%)
|
1,679.05
est: 1,704.00 (-1.5%)
|
1,405.08
est: 1,418.00 (-0.9%)
|
1,291.00
est: 1,366.00 (-5.5%)
|
1,230.41
est: 1,354.00 (-9.1%)
|
496.68
est: 733.00 (-32.2%)
|
1,247.00
1,247.00 – 1,247.00
+70.1% YoY
|
1,335.00
1,335.00 – 1,335.00
+7.1% YoY
|
1,395.00
1,395.00 – 1,395.00
+4.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 2/5 | 4/5 | 1/5 | 2/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex KOSPI 226490.KS | 0.00% | 35.8K | 0.15% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 47.8K | 0.39% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 22.7K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Elia Cho | Director of Global Department & Director | — | — |
| Hong-Joo Yun | Director of Bus. Department, Chief Financial Officer & Director | — | — |
| Taehong Choi | Pres, Chief Executive Officer & Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 293480.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
